<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Barry A Borlaug, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wilson S Colucci, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in patients with current or prior symptoms of HF with a left ventricular ejection fraction (LVEF) ≥50 percent and evidence of cardiac dysfunction as the cause of symptoms (eg, abnormal LV filling pattern and elevated filling pressures) [
         <a href="#rid1">
          1-5
         </a>
         ]. Previously, HFpEF was termed "diastolic HF."
        </p>
        <p>
         The clinical manifestations and diagnosis of patients with HFpEF will be reviewed here.
        </p>
        <p>
         Issues related to pathophysiology, epidemiology, treatment, and prognosis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3479.html" rel="external">
          "Epidemiology of heart failure"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120053">
          (Related Pathway(s):
          <a class="utd-content-120053" href="/pathway/120053?topicRef=3504&amp;source=see_link">
           Heart failure: Diagnosis and classification
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p>
         Asymptomatic LV diastolic dysfunction is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/131241.html" rel="external">
          "Asymptomatic left ventricular diastolic dysfunction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p>
         The clinical manifestations of HFpEF are generally the same as those for other forms of HF (eg, HF with reduced ejection fraction [HFrEF]) [
         <a href="#rid6">
          6-8
         </a>
         ]. Dyspnea (including dyspnea on exertion, paroxysmal nocturnal dyspnea, and orthopnea) and fatigue are the most common symptoms of HFpEF  (
         <a class="graphic graphic_table graphicRef120329" href="/z/d/graphic/120329.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. Exertional chest pain is also a common presentation in patients with HFpEF [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         In general, signs and symptoms alone cannot be used to differentiate HFpEF from HFrEF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report in which the clinical data from 59 patients aged at least 60 years old with symptoms of HF and an LVEF ≥50 percent were compared with data from 60 patients of the same age with HF and an LVEF ≤35 percent and with data from 28 age-matched healthy controls, the patients with HFpEF had similar clinical manifestations (including peak oxygen consumption [VO
         <sub>
          2
         </sub>
         ] and neurohumoral activation) to those with HFrEF, although some parameters were less severe (natriuretic peptide levels, some quality-of-life measures) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In other series, cardiopulmonary exercise parameters, central cardiac filling pressures, and pulmonary hypertension severity were indistinguishable between patients with HFpEF and HFrEF [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H675079040">
         <span class="h2">
          When to suspect HFpEF
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suspect HFpEF if the history or physical examination reveal at least one symptom  (
         <a class="graphic graphic_table graphicRef120329" href="/z/d/graphic/120329.html" rel="external">
          table 1
         </a>
         ) of HF that is not sufficiently explained by another diagnosis. In patients with symptoms of HF, the presence of certain conditions increases the likelihood that HFpEF is present:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≥60 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronary artery disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial fibrillation (AF)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic kidney disease
        </p>
        <p>
        </p>
        <p>
         In the presence of a noncardiac disease that causes HF-like symptoms or a cardiac disease that causes HF, we consider the following prior to evaluation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presence of a noncardiac disease that mimics HF
         </strong>
         –
         <strong>
         </strong>
         In patients with a history of a noncardiac disease (eg, obesity, chronic kidney disease) that may cause one or more of the signs or symptoms of HF, HFpEF may contribute to the overall burden of symptoms. In such cases, the decision to pursue the diagnosis of HFpEF depends on the likelihood that treatment of HFpEF would improve the patient's symptoms, reduce the risk of adverse events attributable to HFpEF (eg, hospitalization), alter management of preexisting disease, or inform prognosis. (See
         <a class="local">
          'Noncardiac conditions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presence of another cardiac disease
         </strong>
         – In the presence of a cardiac disease known to cause the clinical syndrome of HF or that is associated with the presence of diastolic dysfunction, we typically do not pursue the diagnosis of HFpEF. Such diseases include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiomyopathy (eg, hypertrophic or restrictive cardiomyopathy)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiac amyloidosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant valve disease (moderate or severe stenosis or regurgitation)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pericardial disease (eg, constrictive pericarditis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High-output HF
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3246054282">
         <span class="h2">
          Diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with suspected HFpEF, we suggest the following approach to evaluation  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H3518250603">
         <span class="h3">
          Initial testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of patients with suspected HFpEF commonly includes the following tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiograph
         </strong>
         – A chest radiograph is commonly obtained in patients with HF to assess for signs of pulmonary edema and identify other causes of dyspnea. The chest radiograph may show cardiomegaly with or without evidence of pulmonary edema. Most patients with HFpEF have a normal chest radiograph [
         <a href="#rid14">
          14
         </a>
         ]. Thus, normal chest radiography does not exclude HFpEF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECG
         </strong>
         – An electrocardiogram (ECG) is routinely performed in patients with HF, although the findings are often nonspecific. Evidence of myocardial ischemia or prior infarction may be present. AF is observed in approximately 40 to 50 percent of patients with HFpEF, and the lifetime risk of AF in patients with HFpEF is approximately 67 percent [
         <a href="#rid15">
          15
         </a>
         ]. The presence of AF on ECG in a patient with normal LVEF and dyspnea increases the odds that HFpEF is present by more than 20-fold [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echocardiography
         </strong>
         – If echocardiography has not been performed, we obtain a complete Doppler echocardiogram. Echocardiography can identify abnormal diastolic function and other causes of HF (eg, pericardial disease, valve disease), and is required to calculate the H
         <sub>
          2
         </sub>
         FPEF score. (See
         <a class="local">
          'Assessment after initial testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Key measures obtained by echocardiography include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Left ventricular ejection fraction
         </strong>
         – The presence of an LVEF ≥50 percent is required for the diagnosis of HFpEF. (See
         <a class="medical medical_review" href="/z/d/html/5331.html" rel="external">
          "Tests to evaluate left ventricular systolic function", section on 'Echocardiography'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary artery systolic pressure
         </strong>
         – Elevation in pulmonary artery systolic pressure (PASP) estimated by echocardiography is common in patients with HFpEF, and the identification of an elevated PASP in an older patient with dyspnea raises suspicion for the diagnosis of HFpEF [
         <a href="#rid17">
          17
         </a>
         ]. PASP &gt;35 mmHg is a criterion of HFpEF diagnostic scores.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Methodology for estimating PASP and limitations of such estimates are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83974.html" rel="external">
          "Echocardiographic assessment of the right heart", section on 'Pulmonary artery pressure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Signs of abnormal diastolic function and elevated filling pressures
         </strong>
         – Echocardiography can be used to measure functional parameters suggestive of diastolic dysfunction (eg, E/e’ ratio) that support the diagnosis of HFpEF. The approach to echocardiographic assessment of diastolic dysfunction is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The findings of left atrial enlargement or concentric LV remodeling or hypertrophy can support the diagnosis of HFpEF or lead the clinician to suspect HFpEF but are not necessary to reach the formal diagnosis of HFpEF.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If structural parameters cannot be adequately measured by echocardiography, we suggest obtaining cardiovascular magnetic resonance imaging, although slight differences in measures among imaging modalities have been reported [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Natriuretic peptides
         </strong>
         – We do not typically obtain a natriuretic peptide level as a component of the initial evaluation, but some experts do obtain either a B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) level as part of initial testing. The use of BNP in the diagnosis of HFpEF is discussed elsewhere in this topic. (See
         <a class="local">
          'Approach to additional testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2312434754">
         <span class="h3">
          Assessment after initial testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         After initial testing, we evaluate whether the following are present  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one symptom or sign of HF
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of an LVEF ≥50 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No apparent cause of HF symptoms other than HFpEF
        </p>
        <p>
        </p>
        <p>
         In patients without one or more of these factors, isolated HFpEF is unlikely to be present. However, some patients may nonetheless have HFpEF caused by another cardiac disease, such as valve disease, pulmonary arterial hypertension, or pericardial disease. In such cases, we suggest referral to a general cardiologist or HF cardiologist to determine whether HFpEF is present and the best approach to treatment.
        </p>
        <p>
         In patients in whom all three factors are present, we calculate the likelihood that HFpEF is present. We prefer to use the "Heavy, Hypertensive, atrial Fibrillation, Pulmonary hypertension, Elder, and Filling pressure" (H
         <sub>
          2
         </sub>
         FPEF) score (
         <a class="calc calc_professional" href="/z/d/html/141489.html" rel="external">
          calculator 1
         </a>
         ), which estimates the likelihood that symptoms are best explained by HFpEF. The score is the sum of points assigned to the following clinical variables (scores range 0 to 9)  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          H
         </strong>
         eavy – Body mass index &gt;30 kg/m
         <sup>
          2
         </sup>
         (2 points) (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          H
         </strong>
         ypertensive – Hypertensive and treated with two or more antihypertensive medicines (1 point).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial
         <strong>
          F
         </strong>
         ibrillation – Any history of paroxysmal or persistent AF (3 points).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          P
         </strong>
         ulmonary hypertension – PASP &gt;35 mmHg using Doppler echocardiography (1 point).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          E
         </strong>
         lder – Age &gt;60 years (1 point).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          F
         </strong>
         illing pressure – Doppler echocardiographic E/e' &gt;9 (1 point) where E is the peak velocity of early LV filling and e' is the peak early diastolic velocity of LV myocardium adjacent to the mitral annulus by tissue Doppler.
        </p>
        <p>
        </p>
        <p>
         The likelihood that HFpEF is present depends on the H
         <sub>
          2
         </sub>
         FPEF score value  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          0 points
         </strong>
         – In patients with a H
         <sub>
          2
         </sub>
         FPEF score of 0, the likelihood that HFpEF is the cause of symptoms is low (ie, 14 percent); in such cases, we typically search for other causes of the patient’s symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          1 to 5 points
         </strong>
         – In patients with 1, 2, 3, 4, or 5 points, the likelihood that HFpEF is the cause of symptoms is low or intermediate (ie, 24, 40, 56, 72, and 84 percent); in such cases, additional testing is required. (See
         <a class="local">
          'Approach to additional testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6 or more points
         </strong>
         – In patients with 6, 7, 8, or 9 points, HFpEF is the most likely the cause of symptoms (ie, 91, 95, 98, and 99 percent), and no further testing for the cause of symptoms is required.
        </p>
        <p>
        </p>
        <p>
         The American guidelines mention the use of diagnostic scores and state no preference for use of a specific score [
         <a href="#rid19">
          19
         </a>
         ]. The European Society of Cardiology favors use of the "Heart Failure Association Pretest assessment, Echocardiography and natriuretic peptide, Functional testing, Final etiology" (HFA-PEFF) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Our preference to use a score to diagnose HFpEF is based on the syndromic nature of HFpEF. In our experience and based on limited data, other approaches to diagnosis (eg, single criterion from echocardiography, natriuretic peptide levels) are less accurate for the diagnosis of HFpEF. The H
         <sub>
          2
         </sub>
         FPEF score has greater accuracy than the HFA-PEFF score and was validated using the gold standard of exercise hemodynamic measurements [
         <a href="#rid20">
          20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that included patients who underwent a hemodynamic exercise test, the H
         <sub>
          2
         </sub>
         FPEF score had a higher diagnostic accuracy than the HFA-PEFF score (area under the receiver operator curve 0.85 versus 0.71; difference 0.13, 95% CI 0.1-0.18) [
         <a href="#rid21">
          21
         </a>
         ]. The accuracy of the H
         <sub>
          2
         </sub>
         FPEF score was higher in all subgroups tested (eg, patients with or without obesity, AF, elevated BNP levels, chronic kidney disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The H
         <sub>
          2
         </sub>
         FPEF score was derived based on data from 414 patients with an LVEF ≥50 percent (267 with HFpEF and 147 with noncardiac dyspnea) and validated in a test cohort of 100 patients (61 with HFpEF) [
         <a href="#rid14">
          14
         </a>
         ]. Diagnoses for all patients were validated by an invasive hemodynamic exercise test. The odds of HFpEF doubled for each one-unit increase in the H
         <sub>
          2
         </sub>
         FPEF score (odds ratio 1.98, 95% CI 1.74-2.30), and area under the curve was 0.84. The H
         <sub>
          2
         </sub>
         FPEF score was more accurate than an algorithm based on expert consensus (increase in area under the curve of 0.17, 95% CI 0.12-0.22). Inclusion of natriuretic peptide levels did not improve the accuracy of the model.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H881603893">
         <span class="h3">
          Approach to additional testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients in whom there remains a clinical suspicion for HFpEF but in whom the H
         <sub>
          2
         </sub>
         FPEF score does not suggest the presence of HFpEF (ie, score between 1 and 5), we perform additional testing  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First, natriuretic peptide testing
         </strong>
         – In patients in whom there is diagnostic uncertainty after initial testing, the next step in evaluation is to obtain a serum natriuretic peptide level (ie, BNP or NT-proBNP). However, in patients with chronic kidney disease and markedly reduced estimated glomerular filtration rate (eGFR; eg, &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) or other conditions (eg, obesity  (
         <a class="graphic graphic_table graphicRef99857" href="/z/d/graphic/99857.html" rel="external">
          table 2
         </a>
         )) in which the natriuretic peptide levels are unlikely to accurately represent filling pressures, we suggest referral to a general cardiologist or HF cardiologist to guide further testing. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Impact of conditions and medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients in whom natriuretic peptide levels are unlikely to be markedly influenced by other conditions, the interpretation of the BNP levels for the diagnosis of HFpEF is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the NT-proBNP level is &gt;450 pg/mL or BNP is &gt;150 pg/mL, the presence of HFpEF is highly likely, and no further testing is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the NT-proBNP level is ≤450 pg/mL or BNP is ≤150 pg/mL, the diagnosis of HFpEF is not excluded; there is no rule-out value for NT-proBNP or BNP. In such patients, additional testing is required  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the diagnosis of HFpEF is not confirmed after BNP testing (eg, natriuretic peptide level not representative of filling pressures, high clinical suspicion), the next step in the diagnostic evaluation is measurement of invasive hemodynamics (see below).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to the use of natriuretic peptides differs from North American and European guidelines, which are unclear on the exact role of natriuretic peptides in the diagnosis of HFpEF [
         <a href="#rid19">
          19,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This approach is based on our experience and limited data that studied different thresholds for BNP levels:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one study, an NT-proBNP level &gt;450 pg/mL was 85 percent specific for HFpEF [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A large series of consecutive patients showed that 60 percent of patients with invasively proven HFpEF had NT-proBNP levels &lt;260 pg/mL, and 37 percent had NT-proBNP levels &lt;125 pg/mL [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further details on BNP testing can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          If uncertainty remains, obtain invasive hemodynamic measurements
         </strong>
         – In patients in whom HFpEF is suspected but cannot be confirmed or excluded by other means, we obtain a right heart catheterization and, if indicated, hemodynamics measured during maneuvers that increase LV filling pressures. Prior to invasive testing, we suggest cardiology consultation to review all available data, review the risks and benefits of invasive testing, and assist with interpretation of right heart catheterization findings [
         <a href="#rid3">
          3,24-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Invasive testing protocol
         </strong>
         – The elements of a hemodynamic for assessment of HFpEF include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pressures should be measured at end-expiration with an open glottis.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If pulmonary capillary wedge pressure (PCWP) is not ≥15 mmHg at rest, we perform invasive measurements with maneuvers to increase LV filling pressures. We typically use supine cycle ergometry (60 rotations per minute beginning at 20 W and increasing by 10 to 20 W increments every two to three minutes until exhaustion) [
         <a href="#rid16">
          16,24
         </a>
         ]. We prefer exercise hemodynamics rather than fluid boluses, leg raises, or other maneuvers designed to load the LV; in patients with HFpEF, exercise causes more pronounced elevations in filling pressures than other maneuvers [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If exercise is not possible, a passive leg raise can be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Invasive test interpretation
         </strong>
         – The interpretation of hemodynamics and the need for exercise testing are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Resting measurements
         </strong>
         – In patients with PCWP ≥15 mmHg at rest, the presence of HFpEF is confirmed. In patients with normal resting filling pressures, the diagnosis of HFpEF is not excluded [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exercise measurements
         </strong>
         – In patients with an increase in PCWP to ≥25 mmHg at any point during a supine exercise effort or maneuver designed to increase LV filling pressures, the presence of HFpEF is confirmed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In patients undergoing upright exercise, if the increase in PCWP relative to the increase in cardiac output exceeds 2 mmHg/L/min, the presence of HFpEF is confirmed [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         In patients without an elevated PCWP with exercise, the diagnosis of HFpEF is excluded.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Right heart catheterization with exercise is recognized as the clinical gold standard for the diagnosis of HFpEF by professional societies [
         <a href="#rid19">
          19,22
         </a>
         ]. However, these societies also recognize the use of a diastolic stress test as a noninvasive option that can be used to diagnose HFpEF. In our experience, diastolic stress tests are difficult to conduct, are not widely available, and have lower accuracy than invasive hemodynamic testing. (See
         <a class="local">
          'Tests with limited value'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, approximately 35 percent of patients with HF have normal PCWP at rest and only exhibit abnormal hemodynamics with exercise [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1994066759">
         <span class="h2">
          Tests with limited value
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tests with an unclear role in the diagnosis of HFpEF include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiopulmonary exercise test
         </strong>
         – Noninvasive cardiopulmonary exercise testing has a limited role in differentiating patients with HF from those with lung disease and deconditioning [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a large study with invasive evaluation for HFpEF, cardiopulmonary exercise testing had low sensitivity and specificity for HFpEF and noncardiac causes of dyspnea [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a large study, a peak oxygen consumption (VO
         <sub>
          2
         </sub>
         ) of less than 14 mL/min/kg was highly specific for HFpEF, and patients with values higher than 20 mL/min/kg were unlikely to have HFpEF. However, peak VO
         <sub>
          2
         </sub>
         between 14 to 20 mL/min/kg neither confirmed nor excluded the presence of HFpEF. (See
         <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">
          "Approach to the patient with dyspnea", section on 'Cardiopulmonary exercise testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Exercise echocardiography
         </strong>
         – Some studies suggest that there may also be a role for exercise echocardiography in the evaluation of HFpEF, but there are conflicting data on its accuracy [
         <a href="#rid25">
          25,30-32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5304.html" rel="external">
          "Echocardiographic evaluation of left ventricular diastolic function in adults", section on 'Tissue Doppler imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H4201099644">
         <span class="h2">
          Noncardiac conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who have an LVEF ≥50 percent and symptoms or signs suggestive of HF (such as shortness of breath, ankle edema, or paroxysmal nocturnal dyspnea), some do not have HF but have one or more other conditions such as obesity, deconditioning, advanced age, venous insufficiency, anemia, or lung disease.
        </p>
        <p class="headingAnchor" id="H1306891257">
         <span class="h2">
          Cardiac conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac diseases that may present with HF  (
         <a class="graphic graphic_table graphicRef54975" href="/z/d/graphic/54975.html" rel="external">
          table 3
         </a>
         ) or that may be complicated by diastolic dysfunction or HFpEF but that require a different approach to management include the following conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coronary artery disease
         </strong>
         – Obstructive coronary artery disease (CAD) can cause exertional dyspnea that can mimic the symptoms of HFpEF. Obstructive CAD may also cause HFpEF. The approach to CAD assessment is described elsewhere in this topic. (See
         <a class="local">
          'Testing for coronary artery disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Restrictive cardiomyopathy
         </strong>
         – Restrictive cardiomyopathy is characterized by nondilated ventricles with severely impaired ventricular filling, which is caused by a variety of familial and nonfamilial conditions. The characteristics of restrictive cardiomyopathy that differentiate it from HFpEF are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4918.html" rel="external">
          "Restrictive cardiomyopathies", section on 'When to suspect RCM'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients diagnosed with HFpEF, cardiac amyloidosis may be present. If there are other signs or symptoms of amyloidosis, further testing for amyloid is required [
         <a href="#rid33">
          33
         </a>
         ]. In addition, a clinical score may be used to identify patients at particularly high risk of cardiac amyloidosis [
         <a href="#rid34">
          34
         </a>
         ]. The signs and symptoms of amyloidosis and the approach to its diagnosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertrophic cardiomyopathy
         </strong>
         – Hypertrophic cardiomyopathy (HCM) is commonly caused by a mutation in one of several sarcomeric genes and is differentiated from HFpEF by characteristic clinical features and echocardiographic findings. (See
         <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">
          "Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to sarcomeric (ie, genetic) HCM, other causes of HCM include glycogen storage disease, lysosomal disease (including Fabry disease), syndromic HCM (eg, Noonan syndrome, LEOPARD syndrome [
         <strong>
          l
         </strong>
         entigines,
         <strong>
          E
         </strong>
         CG abnormalities,
         <strong>
          o
         </strong>
         cular hypertelorism,
         <strong>
          p
         </strong>
         ulmonic stenosis,
         <strong>
          a
         </strong>
         bnormal genitalia,
         <strong>
          r
         </strong>
         etardation of growth, and sensorineural
         <strong>
          d
         </strong>
         eafness], Friedreich ataxia), and familial amyloidosis (transthyretin [TTR] or apolipoprotein mutation). (See
         <a class="medical medical_review" href="/z/d/html/13558.html" rel="external">
          "Noonan syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111807.html" rel="external">
          "Congenital and inherited hyperpigmentation disorders", section on 'LEOPARD syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">
          "Friedreich ataxia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4912.html" rel="external">
          "Inherited syndromes associated with cardiac disease", section on 'Metabolic disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noncompaction
         </strong>
         – LV noncompaction (LVNC) is a cardiomyopathy characterized by prominent LV trabeculae and deep intertrabecular recesses, resulting in a thickened myocardium consisting of a noncompacted layer and a thin compacted layer. Although LVNC was traditionally considered a developmental anomaly, acquired cases have been reported. Although many patients with HF and LVNC have a reduced LVEF, some have an LVEF ≥50 percent. (See
         <a class="medical medical_review" href="/z/d/html/4924.html" rel="external">
          "Isolated left ventricular noncompaction in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Valve disease
         </strong>
         – This is generally differentiated from HFpEF by echocardiography showing abnormal valve function. Of note, many patients with HFpEF also display some evidence of valvular heart disease, but not in the severe range. Mild to moderate valve lesions in patients with HFpEF are generally considered to be "bystanders" rather than causal of HF symptoms; nonsevere mitral and tricuspid regurgitation are common in HFpEF. The presence of mild to moderate mitral regurgitation in HFpEF is an indicator of more severe left atrial myopathy and is also related to the presence of atrial fibrillation [
         <a href="#rid35">
          35
         </a>
         ]. Tricuspid regurgitation is also commonly associated with AF and also suggests the presence of right HF [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericardial disease
         </strong>
         – Pericardial disease, such as constrictive pericarditis, can be differentiated from isolated HFpEF with echocardiography or other tests. (See
         <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">
          "Constrictive pericarditis: Diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-output heart failure
         </strong>
         – High-output HF may present similarly to HFpEF and has many of the same features. The presence of an elevated cardiac index and chamber enlargement at rest suggest the presence of a high-output state. (See
         <a class="medical medical_review" href="/z/d/html/113041.html" rel="external">
          "Clinical manifestations, diagnosis, and management of high-output heart failure", section on 'When to suspect high-output heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstructive heart disease
         </strong>
         – An obstructive lesion in great vessel or heart, such as an intracardiac mass or pulmonary vein stenosis can mimic HFpEF. Cardiac masses are typically evident on echocardiography, while pulmonary vein stenosis is suggested by symptoms and an appropriate history (eg, history of catheter ablation near or within pulmonary veins). The evaluation for these conditions is described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">
          "Cardiac tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation", section on 'Pulmonary vein stenosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Right-sided heart failure
         </strong>
         – Right HF due to non-HFpEF causes (including right ventricular [RV] infarction, arrhythmogenic RV cardiomyopathy, and pulmonary arterial hypertension not due to left heart disease) may present similarly to HFpEF. These diagnoses are usually suggested by echocardiography. (See
         <a class="medical medical_review" href="/z/d/html/75.html" rel="external">
          "Right ventricular myocardial infarction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4931.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Anatomy, histology, and clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, many patients with HFpEF display concurrent RV dysfunction, tricuspid insufficiency, and right HF, or go on to develop right HF that may be difficult to distinguish from the above causes of right HF when followed longitudinally [
         <a href="#rid37">
          37-39
         </a>
         ]. The development of right HF is associated with worse outcomes. A majority of patients with HFpEF (&gt;80 percent) also display pulmonary hypertension (PH) secondary to chronic elevation in left heart pressures, and RV dysfunction associated with PH is also common [
         <a href="#rid17">
          17,37,38
         </a>
         ]. It is important to distinguish PH caused by HFpEF from other types of PH. (See
         <a class="medical medical_review" href="/z/d/html/112486.html" rel="external">
          "Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4000598304">
         <span class="h1">
          TESTING FOR CORONARY ARTERY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAD is common in patients HFpEF, seen in approximately two-thirds of patients in angiographic and autopsy studies, and is a potentially reversible cause of HFpEF [
         <a href="#rid40">
          40-42
         </a>
         ]. We evaluate for CAD in the following scenarios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms suggestive of obstructive CAD
         </strong>
         – In patients with HFpEF who have symptoms that suggest the presence of obstructive CAD (eg, angina, dyspnea on exertion), which may be anginal equivalents, or who have signs of myocardial infarction or ischemia on imaging, we suggest an evaluation for CAD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          New diagnosis of HFpEF and known CAD
         </strong>
         – In patients who present with HFpEF and known CAD without angina, we evaluate for the presence of ischemia unless the patient is not eligible for revascularization [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1534.html" rel="external">
          "Stress testing for the diagnosis of obstructive coronary heart disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1502.html" rel="external">
          "Selecting the optimal cardiac stress test"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic patients without history of CAD
         </strong>
         – In patients with HFpEF and no history of CAD, we do not routinely test for obstructive CAD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2330938668">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">
          "Society guideline links: Heart failure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86003.html" rel="external">
          "Patient education: Heart failure with preserved ejection fraction (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3446.html" rel="external">
          "Patient education: Heart failure (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8680985">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The clinical manifestations of HFpEF are generally the same as those for other forms of HF (eg, HF with reduced ejection fraction [HFrEF])  (
         <a class="graphic graphic_table graphicRef120329" href="/z/d/graphic/120329.html" rel="external">
          table 1
         </a>
         ). Exertional chest pain is also a common presentation in patients with HFpEF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect HF
         </strong>
         – We suspect HFpEF if the history or physical examination reveal at least one symptom  (
         <a class="graphic graphic_table graphicRef120329" href="/z/d/graphic/120329.html" rel="external">
          table 1
         </a>
         ) of HF that is not sufficiently explained by another diagnosis. In patients with symptoms of HF, the presence of certain factors (eg, age &gt;60 years, hypertension, diabetes) increases the likelihood of HFpEF  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'When to suspect HFpEF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial testing
         </strong>
         – The initial testing for HFpEF includes a chest radiograph, ECG, and echocardiography. (See
         <a class="local">
          'Initial testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment after initial testing
         </strong>
         – After initial testing, we evaluate whether the following are present  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Assessment after initial testing'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At least one symptom or sign of HF
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evidence of a left ventricular ejection fraction (LVEF) ≥50 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No apparent cause of HF symptoms other than HFpEF
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients without one or more of these factors, HFpEF is unlikely to be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients in whom all these factors are present, we calculate the likelihood that HFpEF is present. We prefer to use the "Heavy, Hypertensive, atrial Fibrillation, Pulmonary hypertension, Elder, and Filling pressure" (H
         <sub>
          2
         </sub>
         FPEF) score (
         <a class="calc calc_professional" href="/z/d/html/141489.html" rel="external">
          calculator 1
         </a>
         ), which estimates the likelihood that symptoms are best explained by HFpEF  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          0 points
         </strong>
         – In patients with a H
         <sub>
          2
         </sub>
         FPEF score of 0 points, the likelihood that HFpEF is the cause of symptoms is low; in such cases, we typically search for other causes of the patient's symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          1 to 5 points
         </strong>
         – In patients with 1, 2, 3, 4, or 5 points, the likelihood that HFpEF is the cause of symptoms is intermediate; in such cases, additional testing is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          6 or more points
         </strong>
         – In patients with 6, 7, 8, or 9 points, HFpEF is most likely the cause of symptoms, and no further testing for the cause of symptoms is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to additional testing
         </strong>
         – In patients in whom there remains a clinical suspicion for HFpEF but in whom the H
         <sub>
          2
         </sub>
         FPEF score does not suggest the presence of HFpEF (ie, score between 2 and 5, score of 1 and high clinical suspicion), we perform additional testing  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Natriuretic peptide testing
         </strong>
         – In patients in whom there is diagnostic uncertainty after initial testing, the next step in evaluation is to obtain a serum natriuretic peptide level (ie, B-type natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP]). However, in patients with chronic kidney disease and markedly reduced estimated glomerular filtration rate (eGFR; eg, &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         ) or other conditions (eg, obesity  (
         <a class="graphic graphic_table graphicRef99857" href="/z/d/graphic/99857.html" rel="external">
          table 2
         </a>
         )) in which the natriuretic peptide levels are unlikely to accurately represent filling pressures, we suggest referral to a general cardiologist or HF cardiologist to guide further testing. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Impact of conditions and medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In patients in whom natriuretic peptide levels are unlikely to be markedly influenced by other conditions, the interpretation of the BNP levels for the diagnosis of HFpEF is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If the NT-proBNP level is &gt;450 pg/mL or BNP is &gt;150 pg/mL, the presence of HFpEF is highly likely, and no further testing is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If the NT-pro-BNP level is ≤450 pg/mL or BNP is ≤150 pg/mL, the diagnosis of HFpEF is not excluded; NT-proBNP and BNP cannot be used to rule out HFpEF. In such patients, additional testing is required  (
         <a class="graphic graphic_algorithm graphicRef141464" href="/z/d/graphic/141464.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          If uncertainty remains, invasive hemodynamic testing
         </strong>
         – In patients in whom HFpEF is suspected but cannot be confirmed or excluded by other means, we obtain a right heart catheterization and, if indicated, hemodynamics measured during maneuvers that increase LV filling pressures. (See
         <a class="local">
          'Approach to additional testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tests with limited value
         </strong>
         – Tests with limited value include cardiopulmonary exercise testing and exercise echocardiography. (See
         <a class="local">
          'Tests with limited value'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Among patients who have an LVEF ≥50 percent and symptoms or signs suggestive of HF, some do not have HF but have one or more other conditions such as obesity, deconditioning, advanced age, venous insufficiency, or lung disease. (See
         <a class="local">
          'Noncardiac conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cardiac diseases that may present with HF  (
         <a class="graphic graphic_table graphicRef54975" href="/z/d/graphic/54975.html" rel="external">
          table 3
         </a>
         ) or that may be complicated by diastolic dysfunction or HFpEF but that require a different approach to management include coronary artery disease (CAD), hypertrophic cardiomyopathy (HCM), and cardiac amyloidosis. (See
         <a class="local">
          'Cardiac conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testing for coronary artery disease
         </strong>
         – In patients with suspected HFpEF whose history is not concerning for new or worsening angina, we do not routinely test for the presence of CAD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2219617">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         The UpToDate editorial staff acknowledges Michael R Zile, MD, who contributed to earlier versions of this topic review.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges William H Gaasch, MD (deceased), and William C Little, MD (deceased), who contributed to earlier versions of this topic.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014; 115:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep 2014; 16:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YN, Borlaug BA. Heart Failure With Preserved Ejection Fraction. Curr Probl Cardiol 2016; 41:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005; 47:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson KJ, Lee DC, Goroll AH, et al. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985; 38:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 1988; 77:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail 2018; 11:e004962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mentz RJ, Broderick S, Shaw LK, et al. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). J Am Coll Cardiol 2014; 63:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288:2144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farr MJ, Lang CC, Lamanca JJ, et al. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol 2008; 102:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 2018; 138:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013; 128:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Obokata M, Gersh BJ, Borlaug BA. High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea. Circulation 2018; 137:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40:3297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145:e895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020; 22:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Kaye DM, Handoko ML, et al. Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea. JAMA Cardiol 2022; 7:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:3599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbrugge FH, Omote K, Reddy YNV, et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur Heart J 2022; 43:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Kane GC, Reddy YN, et al. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation 2017; 135:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen MJ, Olson TP, Melenovsky V, et al. Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015; 8:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omote K, Verbrugge FH, Sorimachi H, et al. Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail 2023; 25:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisman AS, Shah RV, Dhakal BP, et al. Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure. Circ Heart Fail 2018; 11:e004750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Olson TP, Obokata M, et al. Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2018; 6:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 2010; 56:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhella PS, Pacini EL, Prasad A, et al. Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging 2011; 4:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos M, Rivero J, McCullough SD, et al. E/e' Ratio in Patients With Unexplained Dyspnea: Lack of Accuracy in Estimating Left Ventricular Filling Pressure. Circ Heart Fail 2015; 8:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Cardiol 2023; 81:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies DR, Redfield MM, Scott CG, et al. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2022; 7:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamargo M, Obokata M, Reddy YNV, et al. Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction. Eur J Heart Fail 2020; 22:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy YNV, Obokata M, Verbrugge FH, et al. Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol 2020; 76:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melenovsky V, Hwang SJ, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130:2310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obokata M, Reddy YNV, Melenovsky V, et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63:2817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammed SF, Hussain S, Mirzoyev SA, et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 2000; 140:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3504 Version 55.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17428822" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951759" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21138935" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24893938" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Heart failure with preserved ejection fraction: current understandings and challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26952248" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Heart Failure With Preserved Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16003646" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnostic criteria for diastolic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4030999" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3342491" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29980595" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24161322" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12413374" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18602522" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cardiopulmonary exercise variables in diastolic versus systolic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22281246" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29792299" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23908348" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29378762" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : High Prevalence of Occult Heart Failure With Preserved Ejection Fraction Among Patients With Atrial Fibrillation and Dyspnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19324256" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504452" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35363499" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31472035" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35830183" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34447992" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35139159" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20543134" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039229" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25342738" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36420788" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29695381" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pulmonary Capillary Wedge Pressure Patterns During Exercise Predict Exercise Capacity and Incident Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29803552" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20813283" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21788358" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26067855" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : E/e' Ratio in Patients With Unexplained Dyspnea: Lack of Accuracy in Estimating Left Ventricular Filling Pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37137592" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36069809" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31908127" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32854840" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24875795" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Right heart dysfunction in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25391518" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30544228" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24768876" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Implications of coronary artery disease in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25552356" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10966547" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
